Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Prediction of true positive lung cancers in individuals with abnormal suspicious chest radiographs: a prostate, lung, colorectal, and ovarian cancer screening trial study.

Tammemagi MC, Freedman MT, Pinsky PF, Oken MM, Hu P, Riley TL, Ragard LR, Berg CD, Prorok PC.

J Thorac Oncol. 2009 Jun;4(6):710-21. doi: 10.1097/JTO.0b013e31819e77ce.

2.

Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Oken MM, Marcus PM, Hu P, Beck TM, Hocking W, Kvale PA, Cordes J, Riley TL, Winslow SD, Peace S, Levin DL, Prorok PC, Gohagan JK; PLCO Project Team..

J Natl Cancer Inst. 2005 Dec 21;97(24):1832-9.

PMID:
16368945
3.

Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation.

Tammemagi CM, Pinsky PF, Caporaso NE, Kvale PA, Hocking WG, Church TR, Riley TL, Commins J, Oken MM, Berg CD, Prorok PC.

J Natl Cancer Inst. 2011 Jul 6;103(13):1058-68. doi: 10.1093/jnci/djr173. Epub 2011 May 23.

4.

Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Hocking WG, Hu P, Oken MM, Winslow SD, Kvale PA, Prorok PC, Ragard LR, Commins J, Lynch DA, Andriole GL, Buys SS, Fouad MN, Fuhrman CR, Isaacs C, Yokochi LA, Riley TL, Pinsky PF, Gohagan JK, Berg CD; PLCO Project Team..

J Natl Cancer Inst. 2010 May 19;102(10):722-31. doi: 10.1093/jnci/djq126. Epub 2010 May 4.

5.

Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Barry SA, Tammemagi MC, Penek S, Kassan EC, Dorfman CS, Riley TL, Commin J, Taylor KL.

J Natl Cancer Inst. 2012 Nov 7;104(21):1647-59. doi: 10.1093/jnci/djs398. Epub 2012 Oct 26.

6.

Randomization to screening for prostate, lung, colorectal and ovarian cancers and thyroid cancer incidence in two large cancer screening trials.

O'Grady TJ, Kitahara CM, DiRienzo AG, Boscoe FP, Gates MA.

PLoS One. 2014 Sep 5;9(9):e106880. doi: 10.1371/journal.pone.0106880. eCollection 2014.

7.

The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.

Gohagan JK, Prorok PC, Hayes RB, Kramer BS; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team..

Control Clin Trials. 2000 Dec;21(6 Suppl):251S-272S.

PMID:
11189683
8.

Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, Mandel JS, Oberman A, O'Brien B, Oken MM, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team..

Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S.

PMID:
11189684
9.

Interval lung cancers not detected on screening chest X-rays: How are they different?

Kvale PA, Johnson CC, Tammem├Ągi M, Marcus PM, Zylak CJ, Spizarny DL, Hocking W, Oken M, Commins J, Ragard L, Hu P, Berg C, Prorok P.

Lung Cancer. 2014 Oct;86(1):41-6. doi: 10.1016/j.lungcan.2014.07.013. Epub 2014 Jul 24.

10.

Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.

Ten Haaf K, Jeon J, Tammem├Ągi MC, Han SS, Kong CY, Plevritis SK, Feuer EJ, de Koning HJ, Steyerberg EW, Meza R.

PLoS Med. 2017 Apr 4;14(4):e1002277. doi: 10.1371/journal.pmed.1002277. eCollection 2017 Apr.

11.

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C.

Clin Trials. 2010 Aug;7(4):303-11. doi: 10.1177/1740774510374091. Epub 2010 Jun 22.

PMID:
20571134
12.

Dietary carbohydrate, glycemic index, glycemic load, and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort.

Shikany JM, Flood AP, Kitahara CM, Hsing AW, Meyer TE, Willcox BJ, Redden DT, Ziegler RG.

Cancer Causes Control. 2011 Jul;22(7):995-1002. doi: 10.1007/s10552-011-9772-1. Epub 2011 May 7.

13.

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.

Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK; PLCO Project Team..

J Natl Cancer Inst. 2005 Mar 16;97(6):433-8.

PMID:
15770007
14.

Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Stallings FL, Ford ME, Simpson NK, Fouad M, Jernigan JC, Trauth JM, Miller DS; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team..

Control Clin Trials. 2000 Dec;21(6 Suppl):379S-389S.

PMID:
11189689
15.

Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort.

Lacey JV Jr, Kreimer AR, Buys SS, Marcus PM, Chang SC, Leitzmann MF, Hoover RN, Prorok PC, Berg CD, Hartge P; Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Project Team..

BMC Cancer. 2009 Mar 17;9:84. doi: 10.1186/1471-2407-9-84.

16.

Diagnostic evaluation following a positive lung screening chest radiograph in the Prostate, Lung, Colorectal, Ovarian (PLCO) Cancer Screening Trial.

Hocking WG, Tammemagi MC, Commins J, Oken MM, Kvale PA, Hu P, Ragard LR, Riley TL, Pinsky P, Beck TM, Prorok PC.

Lung Cancer. 2013 Nov;82(2):238-44. doi: 10.1016/j.lungcan.2013.07.017. Epub 2013 Aug 7.

17.

Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Weissfeld JL, Fagerstrom RM, O'Brien B; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team..

Control Clin Trials. 2000 Dec;21(6 Suppl):390S-399S.

PMID:
11189690
18.

Cumulative incidence of false-positive results in repeated, multimodal cancer screening.

Croswell JM, Kramer BS, Kreimer AR, Prorok PC, Xu JL, Baker SG, Fagerstrom R, Riley TL, Clapp JD, Berg CD, Gohagan JK, Andriole GL, Chia D, Church TR, Crawford ED, Fouad MN, Gelmann EP, Lamerato L, Reding DJ, Schoen RE.

Ann Fam Med. 2009 May-Jun;7(3):212-22. doi: 10.1370/afm.942.

19.

Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial.

Lotan Y, Karam JA, Shariat SF, Gupta A, Roupret M, Bensalah K, Margulis V.

Urol Oncol. 2016 Apr;34(4):167.e9-16. doi: 10.1016/j.urolonc.2015.10.011. Epub 2015 Nov 18.

PMID:
26602092
20.

Validation of Self-Report of Chest X-Ray Exam at a Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Center.

Gren LH, Lamerato LE, Wright P, Marcus PM.

Rev Recent Clin Trials. 2015;10(3):194-9. Review.

PMID:
26238206

Supplemental Content

Support Center